What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Annals of Surgery

• Publication date

  1999-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00000658-199909000-00016PMID 10493490PMCID PMC1420888
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum lipid changes in liver transplantation: effect of steroids withdrawn in a prospective randomized trial under cyclosporine A therapy.

  1999cited by this paper
• Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data.

  1998cited by this paper
• Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients.

  1998cited by this paper
• Kaposi's sarcoma in liver transplant recipients on FK506.

  1998cited by this paper
• Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group.

  1998cited by this paper
• Long-term comparison of tacrolimus versus cyclosporine in liver transplantation

  1998cited by this paper
• Multicenter comparison of first- and second-generation IMx tacrolimus microparticle enzyme immunoassays in liver and kidney transplantation.

  1998cited by this paper
• Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study.

  1998cited by this paper
• High-rate hepatitis and low-rate rejection induced late morbidity and mortality in long-term follow-up after liver transplantation.

  1998cited by this paper
• Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients.

  1998cited by this paper
• A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group.

  1998cited by this paper
• Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.

  1998cited by this paper
• Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation.

  1998cited by this paper
• Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus.

  1998cited by this paper
• Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome.

  1998cited by this paper
• Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506).

  1997cited by this paper
• Cardiovascular risk factors in long‐term followup after orthotopic liver transplantation

  1997cited by this paper
• Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus.

  1997cited by this paper
• De novo malignancies after liver transplantation using tacrolimus‐based protocols or cyclosporine‐based quadruple immunosuppression with an interleukin‐2 receptor antibody or antithymocyte globulin

  1997cited by this paper
• Long-term immunosuppression without corticosteroids after orthotopic liver transplantation: a positive therapeutic aim.

  1996cited by this paper
• Clinical significance of recurrent primary biliary cirrhosis after liver transplantation

  1996cited by this paper
• Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation.

  1996cited by this paper
• Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression.

  1996cited by this paper
• 10 years of pediatric liver transplantation.

  1996cited by this paper
• The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.

  1996cited by this paper
• Randomised trialomania? The multicentre liver transplant trials of tacrolimus.

  1995cited by this paper
• The current status of hepatic transplantation at the University of Pittsburgh.

  1995cited by this paper
• Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.

  1995cited by this paper
• One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.

  1995cited by this paper
• Corticosteroid withdrawal after liver transplantation.

  1995cited by this paper
• Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.

  1994cited by this paper
• Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.

  1994cited by this paper
• Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience.

  1994cited by this paper
• Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506.

  1994cited by this paper
• Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.

  1994cited by this paper
• A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.

  1994cited by this paper
• FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects.

  1994cited by this paper
• INFECTIOUS COMPLICATIONS IN LIVER TRANSPLANT RECIPIENTS ON TACROLIMUS Prospective Analysis of 88 Consecutive Liver Transplants

  1994cited by this paper
• The nephrotoxicity of FK506 as compared with cyclosporine.

  1993cited by this paper
• Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine.

  1993cited by this paper
• Adverse effects of FK 506 overdosage after liver transplantation.

  1993cited by this paper
• A COMPARISON OF RENAL FUNCTION IN CYCLOSPORINE- AND FK‐506-TREATED PATIENTS AFTER PRIMARY ORTHOTOPIC LIVER TRANSPLANTATION

  1993cited by this paper
• CONVERSION OF LIVER ALLOGRAFT RECIPIENTS FROM CYCLOSPORINE TO FK506 IMMUNOSUPPRESSIVE THERAPY—A CLINICOPATHOLOGIC STUDY OF 96 PATIENTS

  1992cited by this paper
• Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.

  1991cited by this paper
• Long-term results after liver transplantation in adults.

  1991cited by this paper
• Adverse effects associated with the use of FK 506.

  1991cited by this paper
• Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.

  1991cited by this paper
• In vivo effect of FK506 on human pancreatic islets.

  1991cited by this paper
• Strategy of FK 506 therapy in liver transplant patients: effect of graft function.

  1991cited by this paper
• Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.

  1991cited by this paper
• One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults.

  1991cited by this paper
• Changes in renal function after liver transplantation under FK 506.

  1991cited by this paper
• A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

  1991cited by this paper
• Cyclosporine toxicity to organs other than the kidney.

  1991cited by this paper
• Liver transplantation under cyclosporine: a decade of experience.

  1991cited by this paper
• Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.

  1991cited by this paper
• Neurologic complications of FK 506.

  1991cited by this paper
• The question of FK 506 nephrotoxicity after liver transplantation.

  1991cited by this paper
• Oral glucose tolerance test in liver recipients treated with FK 506.

  1990cited by this paper
• Early trials with FK 506 as primary treatment in liver transplantation.

  1990cited by this paper
• Expessive dysphasia possibly related to FK506 in two liver transplant recipients

  1990cited by this paper
• The effects of FK 506 on renal function after liver transplantation.

  1990cited by this paper
• Liver, Kidney, and Thoracic Organ Transplantation Under FK 506

  1990cited by this paper
• Assay of FK 506 in plasma.

  1990cited by this paper
• Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation.

  1990cited by this paper
• Expressive dysphasia possibly related to FK506 in two liver transplant recipients.

  1990cited by this paper
• Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

  1990cited by this paper
• FK 506 for liver, kidney, and pancreas transplantation.

  1989cited by this paper
• Beyond 1 year after liver transplantation.

  1989cited by this paper
• SERIAL DECREASE IN GLOMERULAR FILTRATION RATE IN LONG‐TERM PEDIATRIC LIVER TRANSPLANTATION SURVIVORS TREATED WITH CYCLOSPORINE

  1989cited by this paper
• Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report.

  1988cited by this paper
• AN ANALYSIS OF CYCLOSPORINE EFFICACY AND TOXICITY AFTER LIVER TRANSPLANTATION

  1988cited by this paper
• South Africa: medical care of detainees.

  1985cited by this paper
• Cyclosporine immunosuppression.

  1983cited by this paper

• Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients

  2024cites this paper
• Immunotherapy for head and neck cancer: Fundamentals and therapeutic development.

  2024cites this paper
• Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects

  2023cites this paper
• Adverse reactions and toxic side effects of Tacrolimus

  2022cites this paper
• Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer

  2020cites this paper
• Incisional hernia after liver transplantation: mesh-based repair and what else?

  2020cites this paper
• Early post‐operative intravenous tacrolimus in pediatric liver transplant recipients is not superior to oral tacrolimus

  2019cites this paper
• Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis

  2019cites this paper
• Tacrolimus Monotherapy in Recipients of Liver Transplant: A Single-Center Experience.

  2019cites this paper
• Association of the PPARγ / PI 3 K / Akt pathway with the cardioprotective effects of tacrolimus in myocardial ischemic / reperfusion injury

  2018cites this paper
• Association of the PPARγ/PI3K/Akt pathway with the cardioprotective effects of tacrolimus in myocardial ischemic/reperfusion injury.

  2018cites this paper
• Risk factors for arterial hypertension after liver transplantation.

  2018cites this paper
• Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure

  2018cites this paper
• Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.

  2018cites this paper
• Impact of recipients with hypertension on the survival after liver transplantation : an analysis of the US national database

  2018cites this paper
• PREVALENCE AND RISK FACTORS OF HYPERKALEMIA AFTER LIVER TRANSPLANTATION

  2018cites this paper
• Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients

  2017cites this paper
• Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.

  2017cites this paper
• Immunotherapy in head and neck cancer

  2017cites this paper
• Pediatric Liver Transplantation

  2016cites this paper
• Evaluación de la relevancia clínica de diversas variantes de los genes CYP3A4, CYP3A5 y ABCB1 sobre ciclosporina y tacrolimus en trasplante hepático

  2016cites this paper
• Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge.

  2015cites this paper
• Liver Resection for Early Stage Hepatocellular Carcinoma

  2015cites this paper
• The effects of tacrolimus on the activity and expression of tissue factor in the rat ovary with ischemia-reperfusion induced injury.

  2015cites this paper
• Insuffisance rénale aiguë et chronique au décours de la transplantation d’organe, rein exclu

  2015cites this paper
• Risk factors of metabolic syndrome after liver transplantation.

  2015cites this paper
• Immunology and Immunotherapy of Head and Neck Cancer.

  2015cites this paper
• Kardio- und zerebrovaskuläre Risiko- Stratifikation nach Lebertransplantation: Überprüfung von Risiko- Scores anhand retrospektiver Analyse eines Kollektivs von 313 Patienten mit 20- Jahres- Follow- Up

  2015cites this paper
• Clinical Allograft Rejection Syndromes in Liver Transplantation

  2014cites this paper
• Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patients.

  2014cites this paper
• Association between CYP 3 A 5 Genotypes in Graft Liver and Increase in Tacrolimus Biotransformation from Steroid Treatment in Living-donor Liver Transplant Patients

  2014cites this paper
• Calcineurin inhibitors and hypertension: a role for pharmacogenetics?

  2014cites this paper
• Safety and efficacy of four steroid‐minimization protocols in liver transplant recipients: 3‐year follow‐up in a single center

  2013cites this paper
• Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.

  2013cites this paper
• Combination Treatment to Target KIT Mutant Cells

  2013cites this paper
• Pathogenesis of calcineurin inhibitor-induced hypertension.

  2012cites this paper
• 1000 liver transplantations at the Department of General, Transplant and Liver Surgery, Medical University of Warsaw--analysis of indications and results.

  2012cites this paper
• Hypertension in solid organ transplant recipients.

  2012cites this paper
• Immunology of Head and Neck Cancer

  2011cites this paper
• Arterial hypertension in liver transplant recipients.

  2011cites this paper
• Management of hypertension in liver transplant patients.

  2011cites this paper
• Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection

  2011cites this paper
• The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension

  2011cites this paper
• One Thousand Consecutive Primary Liver Transplants Under Tacrolimus Immunosuppression: A 17- to 20-Year Longitudinal Follow-Up

  2011cites this paper
• Medical epidemiology of patients surviving ten years after liver transplantation

  2011cites this paper
• Estrategias de optimización del trasplante hepático

  2010cites this paper
• Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model

  2010cites this paper
• Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.

  2010cites this paper
• Liver Transplantation for Alcoholic Liver Disease in Europe: A Study from the ELTR (European Liver Transplant Registry)

  2010cites this paper
• Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.

  2009cites this paper
• Management of the liver transplant patient

  2009cites this paper
• Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction

  2009cites this paper
• Long‐term Management of the Liver Transplant Patient: Recommendations for the Primary Care Doctor

  2009cites this paper
• Management of Early Hepatocellular Carcinoma in Patients with Well-Compensated Cirrhosis

  2009cites this paper
• Clinical and pathological analysis of acute rejection following orthotopic liver transplantation.

  2009cites this paper
• Diabetic Hyperosmalar State Caused by Tacrolimus in a Renal Transplant Patient: A Case Report

  2009cites this paper
• Renal function evaluated by measured GFR during follow‐up in pediatric liver transplant recipients

  2009cites this paper
• Recurrent Nonhepatic and De Novo Malignancies After Liver Transplantation

  2009cites this paper
• Incidence and management of colorectal cancer in liver transplant recipients.

  2008cites this paper
• Capítulo 25 – Complicaciones metabólicas

  2008cites this paper
• Sirolimus en trasplante de rgano slido peditrico: Experiencia en 5 casos

  2008cites this paper
• Long‐term results after liver transplantation

  2008cites this paper
• Should trichrome stain be used on all post–liver transplant biopsies with hepatitis c virus infection to estimate the fibrosis score?

  2008cites this paper
• Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow‐up

  2008cites this paper
• Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile.

  2008cites this paper
• The burden of chronic kidney disease in long-term liver transplant recipients.

  2008cites this paper
• Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction

  2008cites this paper
• [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].

  2008cites this paper
• Nephrotoxicity of calcineurin and mTOR inhibitors

  2008cites this paper
• Evaluation of the Immunossupressive Regimen Composed of Sirolimus, Cyclosporin and Prednisone in a Group of Renal Graft Recipients

  2007cites this paper
• Randomized trial of tacrolimus monotherapy: tacrolimus in combination, tacrolimus alone compared (the TICTAC trial).

  2007cites this paper
• Review article: medical management of the liver transplant recipient – a primer for non‐transplant doctors

  2007cites this paper
• Avoiding calcineurin inhibitors in the early post‐operative course in high‐risk liver transplant recipients: The role of extracorporeal photopheresis

  2007cites this paper
• Liver Transplantation and Hepatocellular Carcinoma

  2007cites this paper
• Survie et complications médicales à long terme : 10 ans après transplantation hépatique

  2007cites this paper
• Kidney Transplantation With Sirolimus and Mycophenolate Mofetil–Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs

  2007cites this paper
• Validation of cardiovascular risk scores in a liver transplant population

  2006cites this paper
• Economic evaluation in critical care: a focus on severe sepsis in oncology

  2006cites this paper
• Immunosuppression in heart transplantation: shooting ourselves in the foot!

  2006cites this paper
• The liver transplant recipient: what you need to know for long-term care.

  2006cites this paper
• Long‐term renal function after liver transplantation is related to calcineurin inhibitors blood levels

  2006cites this paper
• Insuffisance rénale aiguë et chronique au décours de la transplantation d'organe, rein exclu

  2006cites this paper
• Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living‐donor liver transplant patients

  2006cites this paper
• Thrombotic and nonthrombotic hepatic artery complications in adults and children following primary liver transplantation with long‐term follow‐up in 1000 consecutive patients *

  2006cites this paper
• [Sirolimus for rescue of recurrent acute rejection and diabetes mellitus after liver transplantation: report of one case].

  2005cites this paper
• Long-Term Outcome of Adding Mycophenolate Mofetil to Tacrolimus for Nephrotoxicity Following Liver Transplantation

  2005cites this paper
• Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk‐factors

  2005cites this paper
• Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation.

  2005cites this paper
• Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile.

  2005cites this paper
• Rituximab (Chimeric Anti-CD20 Antibody) for Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation in Adults: Long-Term Experience from a Single Center

  2005cites this paper
• Nephrotoxic effects of immunosuppressant therapy in pediatric liver transplant recipients.

  2005cites this paper
• Late Complications of Liver Transplantation and Recurrence of Disease

  2005cites this paper
• Induction and Maintenance of Immunosuppression

  2005cites this paper
• Cutaneous infection caused by Alternaria in patients receiving tacrolimus.

  2004cites this paper
• Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction

  2004cites this paper
• Minimizing calcineurin inhibitor drugs in renal transplantation.

  2003cites this paper
• Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation.

  2003cites this paper
• Calcineurin inhibitors and sirolimus

  2003cites this paper
• Refractory acute rejection in a living related liver transplantation.

  2003cites this paper
• Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center’s experience update at 13 years1

  2003cites this paper